Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Summary

TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1, open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-1287 in patients with advanced metastatic or progressive solid tumors who are refractory to, or intolerant of, established therapy known to provide clinical benefit for their condition.

Timeline

Start

2018-12-26

Primary completion

2024-01-10

Completion

2024-01-10

Outcome

Outcome not reported

Stopped: “Sponsor's decision to terminate further development of the program.”

Drugs

Indications